< Back to the Blog

About the author

Ioana Calcev
Ioana Calcev is Chief Operating Officer at Oova. She's dedicated to empowering women with the data and insights they need to understand their hormone health and advocate for better care.

Sources

  1. Divaraniya A, et al. The Oova 2025 State of Perimenopause Report: Real Hormone Data from 10,000+ Women. Oova Inc., 2025. https://cdn.prod.website-files.com/64cd40ea6c8cca864c510895/68efd41a104ba4a5bcb54fd9_Perimenopause%20Report%202025.pdf
  2. Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012;19(4):387–395. doi:10.1097/gme.0b013e31824d8f40
  3. Santoro N, Brown JR, Adel T, Skurnick JH. Characterization of reproductive hormonal dynamics in the perimenopause. J Clin Endocrinol Metab. 1996;81(4):1495–1501. doi:10.1210/jcem.81.4.8636357
  4. Divaraniya A, et al. Hormonal variability across menstrual cycles: real-world data from 4,900+ women. Oova Research. 2026. https://www.oova.life/blog/irregular-menstrual-cycle-hormonal-variability
  5. Prior JC. Progesterone for treatment of symptomatic menopausal women. Climacteric. 2018;21(4):358–365. doi:10.1080/13697137.2018.1472567
  6. Bromberger JT, Kravitz HM. Mood and menopause: findings from the Study of Women's Health Across the Nation (SWAN) over 10 years. Obstet Gynecol Clin North Am. 2011;38(3):609–625. doi:10.1016/j.ogc.2011.05.011
  7. Thurston RC, Joffe H. Vasomotor symptoms and menopause: findings from the Study of Women's Health Across the Nation. Obstet Gynecol Clin North Am. 2011;38(3):489–501. doi:10.1016/j.ogc.2011.05.006
  8. Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175(4):531–539. doi:10.1001/jamainternmed.2014.8063
  9. Rannevik G, Jeppsson S, Johnell O, Bjerre B, Laurell-Borulf Y, Svanberg L. A longitudinal study of the perimenopausal transition: altered profiles of steroid and pituitary hormones, SHBG and bone mineral density. Maturitas. 1995;21(2):103–113. doi:10.1016/0378-5122(94)00869-9
  10. The NAMS 2022 Hormone Therapy Position Statement Advisory Panel. The 2022 hormone therapy position statement of The Menopause Society. Menopause. 2022;29(7):767–794. doi:10.1097/GME.0000000000002028

About the Oova Blog:
Our content is developed with a commitment to high editorial standards and reliability. We prioritize referencing reputable sources and sharing where our insights come from. The Oova Blog is intended for informational purposes only and is never a substitute for professional medical advice. Always consult a healthcare provider before making any health decisions.